Gastric Volvulus Treatment Market Report 2025

The gastric volvulus treatment market size has grown strongly in recent years. It will grow from $27.36 billion in 2024 to $28.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advancements in surgical techniques, improved diagnostic technologies, awareness and education, rise in minimally invasive procedures, research and clinical studies.

The gastric volvulus treatment market size is expected to see strong growth in the next few years. It will grow to $37.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to regulatory changes and approvals, innovations in surgical procedures, growing geriatric population, customized treatment plans, adoption of advanced imaging techniques. Major trends in the forecast period include minimally invasive surgical techniques, awareness and early intervention, research in treatment modalities, collaborative medical practices, and customized treatment approaches.

A growing geriatric population is projected to drive the expansion of the gastric volvulus treatment market in the future. The geriatric population refers to older adults aged 65 and above, who are prone to various diseases due to decreased immunity and aging. Gastric volvulus is primarily seen in individuals over the age of 50. Consequently, the increase in the geriatric population is expected to boost the market. For example, in January 2024, statistics from the Population Reference Bureau (PRB), a US-based nonprofit organization, indicated that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, their share of the total population is projected to grow from 17% to 23%. Therefore, the rising geriatric population is a key driver of the gastric volvulus treatment market.

The rising prevalence of gastrointestinal diseases is anticipated to drive the growth of the gastric volvulus treatment market in the upcoming years. Gastrointestinal diseases refer to medical conditions that affect the internal structures of the gastrointestinal (GI) tract, often referred to as gastrointestinal disorders, including ailments such as gastritis, inflammatory bowel disease, and gastric cancer. The comprehensive care provided during gastric volvulus treatment may encompass strategies and considerations that enhance the overall health of the gastrointestinal system and its related disorders. For example, in September 2022, Cancer Australia, an organization focused on cancer awareness and support for individuals affected by cancer in Australia and its territories, reported that there were an estimated 2,572 new cases of stomach cancer expected to be diagnosed in Australia in 2022 (1,661 males and 911 females). In 2022, the likelihood of developing stomach cancer by age 85 was 1 in 114 (or 0.87%), with the odds being 1 in 1.1 (87%) for men and 1 in 167 (0.60%) for women. Thus, the increasing incidence of gastrointestinal diseases is propelling the gastric volvulus treatment market.

Product innovations emerge as a prominent trend gaining traction in the gastric volvulus treatment market. Major companies in the market are introducing innovative products to maintain their competitive positions. For instance, in October 2023, Pfizer Inc., a pharmaceutical company based in the United States, announced the FDA approval of VELSIPITY (etrasimod) for people with moderate to severe active ulcerative colitis. This once-daily oral sphingosine-1-phosphate (S1P) receptor activator offers a positive benefit-risk profile, providing adults with an effective, steroid-free resolution through a convenient oral pill.

Companies operating in the gastric volvulus treatment market are focusing on product innovations such as digital radiology solutions to enhance radiologists' efficiency. A digital radiology solution involves leveraging digital technology in medical imaging for visualizing internal body structures and aiding in the diagnosis and management of conditions such as gastric volvulus through digital image capture and analysis. For instance, in February 2023, Carestream Health India Pvt. Ltd. launched the DRX Compass, a digital radiological solution designed for accuracy, convenience, and customization. This innovative solution empowers radiologists with heightened productivity and flexibility in configuring the system based on individual requirements.

Key players in the gastric volvulus treatment market are concentrating on developing innovative solutions like advanced hyperbaric oxygen therapy to improve access to cutting-edge medical treatments, thereby enhancing patient outcomes and community health. Advanced hyperbaric oxygen therapy (HBOT) is a medical procedure that involves inhaling 100% oxygen in a pressurized chamber, which enhances oxygen delivery to tissues and promotes healing. This therapy may prove beneficial in the treatment of gastric volvulus by improving tissue oxygenation and aiding recovery from ischemia or surgical procedures. For example, in December 2024, HBOT India, a medical facility in India that specializes in hyperbaric oxygen therapy, introduced Medical Grade 3 ATA Hyperbaric Oxygen Therapy. This treatment enhances healing by increasing oxygen absorption, making it effective for chronic wounds, decompression sickness, and various other conditions. Its launch in Gurgaon significantly broadens access to advanced medical treatments in the area, thereby supporting the health and well-being of the community.

Major companies operating in the gastric volvulus treatment market include PAI Pharma, Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals Inc., Fresenius SE and Co. KGaA, Mayne Pharma Group Limited, Sawai Pharmaceutical Co.Ltd., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Tris Pharma Inc., Pfizer Inc., Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc, Endo International plc, Vintage Labs, Zydus Group, Bayer AG, AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Sanofi S.A., Celltrion Inc., HanAll Biopharma, AstraZeneca plc.

North America was the largest region in the gastric volvulus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the gastric volvulus treatment market report during the forecast period. The regions covered in the gastric volvulus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric volvulus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastric volvulus treatment involves surgical interventions, specifically focusing on volvulus reduction and the reintegration of the stomach into the abdominal cavity, especially in cases of intrathoracic migration. The treatment also addresses the correction of causal factors. Gastric volvulus surgery is typically a straightforward procedure, encompassing de-rotation, lowering of hernial contents into the abdominal wall, and repair of the hernial defect.

The main types of gastric volvulus treatment are organo-axial and mesentero-axial volvulus. Organo-axial volvulus occurs when the abdomen undergoes a 180-degree spin around its long axis, resulting in this condition. Treatment options include medication and surgery, with various routes of administration such as oral and parenteral. Distribution channels for these treatments include hospital pharmacies and retail pharmacies, serving purposes in hospitals, home healthcare, specialty clinics, and other healthcare settings.

The gastric volvulus treatment market research report is one of a series of new reports from. The Business Research Company that provides gastric volvulus treatment market statistics, including gastric volvulus treatment industry global market size, regional shares, competitors with a gastric volvulus treatment market share, detailed gastric volvulus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastric volvulus treatment industry. This gastric volvulus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric volvulus treatment market includes revenues earned by entities that perform laparotomy, gastric detorsion, and gastric fixation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.